Overall, our findings reveal the novel molecular mechanisms of DUXAP9‐206 in mediating the progression of NSCLC and DUXAP9‐206 may serve as a potential target for NSCLC therapy. Here, DUXAP9 is linked to non-small cell lung carcinoma.